Federal Hemp Regulations: 2018 Farm Bill Rules, THC Limits & Compliance

Executive Summary

Federal hemp regulations in the United States operate under a complex framework established by the 2018 Farm Bill, which legalized hemp containing no more than 0.3% delta-9 THC on a dry weight basis. This threshold distinguishes legal hemp from federally controlled marijuana, creating a multi-billion dollar industry spanning CBD products, textiles, construction materials, and dietary supplements. The U.S. Department of Agriculture (USDA) oversees cultivation through approved state and tribal plans, while the Food and Drug Administration (FDA) regulates hemp-derived products in food, drugs, and cosmetics. The Drug Enforcement Administration (DEA) maintains enforcement authority over synthetic cannabinoids and products exceeding THC limits. As of September 2026, the hemp industry faces significant regulatory uncertainty with proposed rules targeting intoxicating hemp-derived cannabinoids like delta-8 THC, THCA, and HHC, which have proliferated in retail markets across states without adult-use marijuana programs. These pending regulations could fundamentally reshape the $28 billion U.S. hemp market, forcing thousands of retailers to reformulate products or exit the market entirely.

Why Federal Hemp Regulations Matter

Federal hemp policy affects approximately 16,000 licensed hemp farmers, 100,000+ retail locations selling hemp-derived products, and millions of consumers who rely on CBD and other cannabinoids for wellness purposes. The economic stakes are substantial: the U.S. hemp industry generated $28.4 billion in retail sales in 2025, according to the Hemp Industry Association, with CBD products accounting for $12.7 billion and intoxicating hemp cannabinoids representing $8.2 billion in sales. The regulatory framework impacts multiple stakeholder groups with competing interests. Farmers in states like Kentucky, North Carolina, and Oregon depend on hemp as a cash crop alternative to tobacco and other declining agricultural commodities. Multi-state operators (MSOs) in the licensed marijuana industry argue that intoxicating hemp products create an unregulated competitor that undermines state-legal cannabis markets and tax revenues. Consumer advocates emphasize access to affordable cannabinoid products, particularly for patients who cannot afford medical marijuana programs or live in states without legal access. Public health officials express concern about unregulated intoxicating products sold without age verification, potency testing, or safety standards. The federal government collects limited tax revenue from hemp compared to potential marijuana taxation, creating fiscal pressure to either regulate hemp more strictly or advance comprehensive cannabis reform. State governments face enforcement challenges as hemp-derived intoxicating products flow across state lines, complicating local marijuana prohibition or regulation. The pending regulatory changes could eliminate thousands of small businesses while potentially benefiting large MSOs positioned to capture market share in a more restricted environment.

Background and History: From Prohibition to Legalization

Hemp cultivation in America predates federal prohibition, with the plant serving as a strategic agricultural commodity before becoming collateral damage in marijuana criminalization.

Colonial Era Through Early 20th Century (1600s-1937)

Hemp cultivation arrived with European colonists in the 1600s, becoming a mandatory crop in some colonies due to its utility for rope, sails, and textiles. George Washington and Thomas Jefferson both grew hemp at their estates. The plant remained an important industrial crop through the 19th century, with Kentucky emerging as a major production center. By the early 1900s, hemp production had declined due to competition from imported fibers and synthetic materials, but the plant remained legal and unrestricted.

The Marihuana Tax Act and Controlled Substances Act (1937-1970)

The Marihuana Tax Act of 1937 imposed prohibitive taxes on cannabis cultivation, effectively ending commercial hemp production despite exemptions for industrial purposes. During World War II, the USDA briefly promoted hemp through the "Hemp for Victory" campaign (1942-1945) to replace Asian fiber imports, licensing approximately 150,000 acres of cultivation. After the war, hemp production again ceased. The Controlled Substances Act of 1970 (21 U.S.C. § 801 et seq.) classified marijuana as a Schedule I substance, making no distinction between intoxicating cannabis and industrial hemp. This classification remained unchanged for nearly five decades, forcing U.S. manufacturers to import hemp fiber and seed from Canada, China, and European nations.

State Pilot Programs and the 2014 Farm Bill (2014-2018)

The Agricultural Act of 2014, commonly called the 2014 Farm Bill, created the first federal pathway for hemp cultivation in decades. Section 7606 authorized state departments of agriculture and higher education institutions to establish industrial hemp research pilot programs. These programs could cultivate and study hemp defined as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis—a threshold derived from a 1976 taxonomic study by Canadian researcher Ernest Small. By 2018, 41 states had enacted legislation authorizing hemp pilot programs. Kentucky, Colorado, and Oregon emerged as early leaders, collectively licensing over 30,000 acres. However, the pilot program framework created legal ambiguity: hemp was technically legal under state law for research purposes but remained a Schedule I controlled substance under federal law. Interstate commerce remained restricted, and financial institutions largely refused to serve hemp businesses due to federal prohibition.

The 2018 Farm Bill: Full Legalization (December 2018)

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, fundamentally transformed hemp's legal status. Section 10113 removed hemp from the definition of marijuana in the Controlled Substances Act, explicitly legalizing the cultivation, processing, and sale of hemp and hemp-derived products. The law defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The 2018 Farm Bill assigned regulatory authority to the USDA for cultivation and required states and tribes to submit plans for USDA approval. The law preserved FDA authority over hemp-derived products in food, drugs, and cosmetics, and maintained DEA authority over synthetic cannabinoids. Critically, the law included no restrictions on intoxicating cannabinoids derived from legal hemp, creating a regulatory gap that would spawn a multi-billion dollar market in delta-8 THC, THCA flower, and other psychoactive hemp products.

USDA Implementation and State Plan Approval (2019-2021)

The USDA published an interim final rule on October 31, 2019, establishing the U.S. Domestic Hemp Production Program. The rule required states and tribes to submit plans including licensing procedures, land descriptions, testing protocols, disposal methods for non-compliant plants, and enforcement mechanisms. The USDA required testing for total THC (delta-9 THC plus THCA multiplied by 0.877) within 15 days of harvest, with a 0.3% limit and a 1.0% negligence threshold. The interim rule generated over 4,500 public comments, with farmers objecting to the total THC testing method, the 15-day testing window, and disposal requirements for "hot" crops exceeding 0.3% THC. The USDA published a final rule on January 19, 2021, maintaining most provisions but allowing states to use performance-based sampling and extending some compliance timelines. As of September 2026, the USDA has approved 73 state and tribal hemp plans, with remaining states operating under USDA direct oversight.

The Rise of Intoxicating Hemp Cannabinoids (2019-2026)

The 2018 Farm Bill's silence on intoxicating hemp derivatives created an unregulated market for psychoactive cannabinoids. Delta-8 THC, a naturally occurring cannabinoid present in trace amounts, became widely available in 2019-2020 through chemical conversion from CBD isolate. Manufacturers used isomerization processes to convert CBD into delta-8 THC, creating products with 10-95% delta-8 THC concentration—far exceeding natural levels but derived from legal hemp containing less than 0.3% delta-9 THC. The market expanded rapidly to include delta-10 THC, THC-O acetate, HHC (hexahydrocannabinol), THCP, and THCA flower. THCA (tetrahydrocannabinolic acid) is the non-intoxicating precursor to delta-9 THC found in raw cannabis. When heated through smoking or vaping, THCA converts to delta-9 THC, producing intoxication identical to marijuana. Cultivators began marketing high-THCA hemp flower—plants that test below 0.3% delta-9 THC when raw but convert to intoxicating levels when consumed—as a legal alternative to marijuana. By 2024, intoxicating hemp products were available in gas stations, convenience stores, and online retailers nationwide, including in states without legal marijuana programs. The DEA issued interim final rules in 2020 and 2023 attempting to classify synthetically derived THC as controlled substances, but enforcement remained limited and legal interpretations varied. Several states enacted their own restrictions: Colorado, Oregon, and New York banned delta-8 THC and similar products, while other states imposed age restrictions, potency limits, or registration requirements.

Proposed Federal Restrictions (2025-2026)

In March 2025, the FDA published an advance notice of proposed rulemaking (ANPRM) seeking comments on regulating hemp-derived cannabinoids in food and dietary supplements. The agency cited safety concerns about intoxicating products marketed without clinical evidence, age verification, or adverse event monitoring. In June 2026, the USDA and DEA jointly announced plans for coordinated rulemaking to address intoxicating hemp-derived cannabinoids, with proposed rules expected by December 2026 and final implementation in 2027. Industry sources indicated the rules would likely prohibit or strictly limit delta-8 THC, THCP, THC-O, and high-THCA flower while potentially preserving access to non-intoxicating CBD products.

Key Players in Federal Hemp Regulation

U.S. Department of Agriculture (USDA)

The USDA Agricultural Marketing Service oversees the U.S. Domestic Hemp Production Program, approving state and tribal plans, licensing producers in states without approved plans, and conducting compliance monitoring. The agency requires annual reporting on acreage, production volumes, and testing results. USDA enforcement focuses on ensuring crops test below 0.3% total THC and that farmers follow approved cultivation plans. The agency has licensed approximately 3,200 producers in states operating under federal oversight and maintains a public database of approved state and tribal plans.

Food and Drug Administration (FDA)

The FDA regulates hemp-derived products marketed as food, dietary supplements, drugs, or cosmetics under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.). The agency has maintained that CBD cannot be legally added to food or marketed as a dietary supplement because it was investigated as a drug (Epidiolex) before being marketed in foods. However, FDA enforcement has been limited, focusing primarily on unsubstantiated health claims rather than the presence of CBD itself. The agency issued warning letters to 22 companies between 2019 and 2025 for marketing CBD products with drug claims. FDA Commissioner Dr. Robert Califf stated in congressional testimony in April 2025 that the agency lacks sufficient data to establish safe CBD dosing levels for food use and called for congressional action to clarify regulatory pathways.

Drug Enforcement Administration (DEA)

The DEA maintains authority over controlled substances and synthetic cannabinoids under the Controlled Substances Act. The agency published an interim final rule in August 2020 confirming that hemp-derived extracts containing less than 0.3% delta-9 THC are not controlled substances, but asserting that "synthetically derived" THC remains Schedule I regardless of source material. A subsequent interim final rule in May 2023 attempted to classify delta-8 THC and THC-O as controlled substances, arguing that chemical conversion processes constitute synthetic production. Legal challenges to this interpretation remain pending in federal courts. The DEA works with state and local law enforcement to investigate illegal marijuana operations disguised as hemp farms and to prosecute trafficking of controlled substances.

Hemp Industry Association

The Hemp Industry Association, founded in 1994, represents farmers, processors, manufacturers, and retailers across the hemp supply chain. The organization lobbied extensively for the 2018 Farm Bill provisions and has advocated for FDA regulatory clarity on CBD in food. The association has opposed broad restrictions on intoxicating hemp cannabinoids, arguing that prohibition would harm legitimate businesses and that targeted regulations addressing safety and labeling would be more appropriate. The group reported membership of over 2,500 companies as of 2026.

U.S. Cannabis Council

The U.S. Cannabis Council represents licensed marijuana MSOs and state-legal cannabis businesses. The organization has advocated for federal restrictions on intoxicating hemp products, arguing that unregulated hemp cannabinoids undermine state marijuana programs, evade taxation, and create public health risks. The council supported the proposed 2026 federal rules and has called for comprehensive cannabis reform that would regulate all intoxicating cannabinoids under a unified framework. Executive Director Sarah Gersten stated in July 2026 congressional testimony that intoxicating hemp products represent "a regulatory failure that harms consumers and legitimate businesses alike."

National Association of State Departments of Agriculture (NASDA)

NASDA coordinates state agricultural agencies' implementation of hemp programs and provides feedback to USDA on regulatory challenges. The organization has advocated for flexibility in testing protocols, reasonable negligence thresholds for farmers whose crops test above 0.3% THC, and federal preemption of conflicting state laws that restrict interstate hemp commerce. NASDA members have reported significant enforcement challenges distinguishing legal hemp from marijuana and addressing intoxicating hemp products that technically comply with the 0.3% delta-9 THC limit.

Legal and Regulatory Framework

Federal hemp law operates through a multi-agency framework with overlapping and sometimes conflicting authorities across cultivation, processing, and product marketing.

Statutory Foundation: Agricultural Improvement Act of 2018

The 2018 Farm Bill (Pub. L. 115-334) amended the Agricultural Marketing Act of 1946 (7 U.S.C. § 1621 et seq.) to establish hemp as an agricultural commodity. Section 297A defines hemp and removes it from Schedule I of the Controlled Substances Act. Section 297B requires the USDA to establish a plan for USDA approval of state and tribal hemp production programs. Section 297C authorizes states and tribes to have primary regulatory authority over hemp production within their jurisdictions, subject to USDA approval. The law explicitly preserves FDA authority under 21 U.S.C. § 301 et seq. and maintains federal law enforcement authority over violations. Critically, Section 297D(c) prohibits states from restricting interstate transportation or shipment of hemp or hemp products lawfully produced under a state or tribal plan or the USDA plan. This preemption clause has created conflicts with states attempting to ban intoxicating hemp products, as manufacturers argue that products derived from compliant hemp cannot be restricted.

USDA Regulations: 7 CFR Part 990

The USDA's final rule, codified at 7 CFR Part 990, establishes licensing requirements, sampling and testing procedures, disposal protocols, and reporting obligations. Key provisions include: Licensed producers must report land locations to the Farm Service Agency and submit to annual inspections. Testing must occur within 15 days of anticipated harvest using DEA-registered laboratories. The testing methodology measures total THC: delta-9 THC plus THCA multiplied by 0.877 (the conversion factor accounting for decarboxylation). Crops testing above 0.3% but below 1.0% total THC may be disposed of or remediated if the exceedance was unintentional. Crops above 1.0% total THC trigger negligence findings and potential license suspension. Three negligent violations in five years result in a 10-year ineligibility period. The USDA requires states to report annually on total acreage, number of licenses, testing results, and enforcement actions. The agency maintains authority to audit state programs and can revoke approval if states fail to enforce their plans effectively.

FDA Regulatory Position on Hemp-Derived CBD

The FDA has not established a regulatory pathway for CBD in food or dietary supplements despite widespread market availability. The agency's position, articulated in a May 2019 statement and reaffirmed in subsequent guidance, holds that CBD is excluded from the dietary supplement definition under 21 U.S.C. § 321(ff)(3)(B) because it was investigated as a new drug (Epidiolex, approved in 2018 for epilepsy) before being marketed in supplements. The FDA could authorize CBD in food through a food additive petition or generally recognized as safe (GRAS) notification, but no manufacturer has successfully completed this process. The agency could also exercise enforcement discretion to allow CBD in certain product categories, but has not done so. In practice, FDA enforcement has targeted therapeutic claims rather than CBD presence itself, creating a de facto tolerated market without formal legal authorization. For intoxicating cannabinoids, the FDA has issued warning letters to companies marketing delta-8 THC products, citing concerns about contamination from synthesis processes, lack of safety data, and marketing to children through candy-like products. The agency has not published formal regulations specific to delta-8 THC or other intoxicating hemp cannabinoids as of September 2026.

DEA Interim Final Rules on Synthetic Cannabinoids

The DEA's August 2020 interim final rule (85 FR 51639) implemented the 2018 Farm Bill by removing hemp from Schedule I and confirming that "tetrahydrocannabinols in hemp" are not controlled substances. However, the rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances" and that the definition of THC includes "all isomers of THC including delta-8 THC, delta-9 THC, delta-10 THC, and others." The May 2023 interim final rule (88 FR 28468) attempted to clarify that delta-8 THC produced through chemical conversion of CBD is "synthetically derived" and therefore Schedule I. The rule defined synthetic as "a substance that has been created by a chemical reaction that changes the molecular structure of any starting material." This interpretation would classify most commercially available delta-8 THC as illegal, but the DEA has not conducted widespread enforcement, and legal challenges arguing that conversion from natural CBD does not constitute synthesis remain pending in the U.S. Court of Appeals for the Ninth Circuit.

State-Level Variations and Conflicts

While the 2018 Farm Bill preempts state restrictions on interstate hemp commerce, states retain authority to regulate intrastate production and sales more restrictively than federal law. As of September 2026, state approaches vary significantly: Twelve states have banned delta-8 THC and similar intoxicating hemp cannabinoids: Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Mississippi, Montana, New York, Rhode Island, and Utah. These states prohibit sale and possession of chemically converted cannabinoids, though enforcement varies. Eighteen states have enacted regulatory frameworks for intoxicating hemp products, typically including age restrictions (21+), potency limits (often 5-10mg THC per serving), testing requirements, labeling standards, and retailer registration. States in this category include California, Connecticut, Florida, Illinois, Louisiana, Maryland, Minnesota, Nevada, New Jersey, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, Texas, Vermont, Virginia, and Washington. Twenty states have not enacted specific legislation addressing intoxicating hemp cannabinoids, creating an unregulated market where products are sold without age verification, testing, or potency limits. This category includes Alabama, Georgia, Indiana, Kansas, Kentucky, Maine, Massachusetts, Michigan, Missouri, Nebraska, New Hampshire, New Mexico, North Dakota, Oregon, Pennsylvania, South Dakota, West Virginia, Wisconsin, and Wyoming. The legal landscape creates compliance challenges for multi-state retailers and manufacturers who must navigate conflicting requirements. The preemption clause in the 2018 Farm Bill has generated litigation, with hemp companies challenging state bans as violations of federal law and states arguing that their police powers allow regulation of intoxicating substances regardless of source.

Market and Business Implications

Federal hemp regulations have created a bifurcated market with distinct dynamics for non-intoxicating CBD products, intoxicating hemp cannabinoids, and industrial hemp applications. The CBD market, valued at $12.7 billion in 2025 retail sales, has matured into a mainstream wellness category with products available in major retailers including CVS, Walgreens, Kroger, and Whole Foods. Pricing has declined significantly from early post-legalization levels: wholesale CBD isolate traded at $3,200 per kilogram in 2019 but fell to $420 per kilogram by 2025 due to oversupply and increased production efficiency. Biomass prices similarly collapsed from $40 per pound in 2019 to $2-4 per pound in 2025, forcing many farmers to exit the market. Major consumer packaged goods companies have entered the CBD space, including Unilever (which acquired CBD brand Equilibria in 2024), Molson Coors (which markets CBD beverages through its Truss subsidiary), and Constellation Brands (which invested $4 billion in Canadian cannabis company Canopy Growth). However, FDA regulatory uncertainty has limited investment in food and beverage applications, with most products marketed as topicals or dietary supplements despite questionable legal status. The intoxicating hemp cannabinoid market, estimated at $8.2 billion in 2025, operates primarily through independent retailers, smoke shops, and online platforms. Delta-8 THC products account for approximately 65% of this segment, with THCA flower representing 20% and other cannabinoids (HHC, delta-10 THC, THCP) comprising 15%. Wholesale delta-8 THC distillate prices ranged from $800-1,200 per kilogram in 2025, with retail products typically priced 30-50% below equivalent marijuana products in legal states. The pending federal restrictions announced in June 2026 have created significant market uncertainty. Publicly traded hemp companies including Charlotte's Web Holdings (TSX: CWEB) and cbdMD (NYSE: YCBD) experienced stock price declines of 35-45% following the announcement. Private equity investment in hemp businesses declined 67% in the second quarter of 2026 compared to the prior year, according to Viridian Capital Advisors. Retailers have reported difficulty securing inventory as manufacturers pause production pending regulatory clarity.

Impact on Licensed Marijuana MSOs

Multi-state marijuana operators have advocated for hemp restrictions while positioning to capture market share if regulations eliminate smaller competitors. Curaleaf Holdings (CSE: CURA), the largest U.S. MSO by revenue, stated in its August 2026 earnings call that federal hemp restrictions could increase marijuana sales by 15-20% in states where the company operates, as consumers shift from unregulated hemp products to tested, licensed marijuana. Trulieve Cannabis (CSE: TRUL) similarly projected that Florida's medical marijuana sales could increase by $400-500 million annually if intoxicating hemp products are restricted. However, MSOs face their own regulatory challenges, including Section 280E of the Internal Revenue Code (26 U.S.C. § 280E), which prohibits businesses trafficking in Schedule I substances from deducting ordinary business expenses. Hemp companies, selling federally legal products, can deduct expenses normally, creating a tax advantage that partially offsets lower retail prices. If federal hemp restrictions force consumers toward licensed marijuana, MSOs would benefit from increased sales volume but continue facing 280E tax burdens that hemp competitors avoid.

Financial Services and Banking Access

Hemp businesses have significantly better access to financial services than marijuana companies due to federal legality. Major banks including JPMorgan Chase, Bank of America, and Wells Fargo provide accounts to hemp businesses, and credit card processors accept hemp transactions without the elevated risk ratings applied to marijuana. The SAFE Banking Act, which would protect financial institutions serving state-legal marijuana businesses, has not been enacted as of September 2026, maintaining the banking disparity between hemp and marijuana sectors. This financial access advantage has enabled hemp companies to scale more rapidly than marijuana MSOs in early stages, with lower capital costs and easier access to merchant services. However, the regulatory uncertainty surrounding intoxicating hemp products has caused some financial institutions to exit the sector or impose restrictions on accounts associated with delta-8 THC and similar products.

What Experts Say

Industry stakeholders, regulators, and policy experts hold sharply divergent views on appropriate federal hemp regulation, particularly regarding intoxicating cannabinoids. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, argued in August 2026 congressional testimony that the 2018 Farm Bill legalized all hemp derivatives without restriction and that subsequent attempts to prohibit specific cannabinoids contradict congressional intent. Miller stated that the industry supports reasonable regulations including age restrictions, testing requirements, and labeling standards, but opposes categorical bans on cannabinoids derived from compliant hemp. He emphasized that thousands of small businesses have invested in intoxicating hemp products in reliance on the 2018 Farm Bill framework and that retroactive prohibition would cause widespread economic harm. Dr. Steven Gendel, former FDA senior scientist and current consultant to the Hemp Industry Association, said in a September 2026 interview that CBD has a strong safety profile based on Epidiolex clinical trials and post-market surveillance, with adverse events primarily limited to drug interactions and gastrointestinal effects at high doses. Gendel argued that FDA could establish safe CBD levels in food through existing regulatory pathways and that continued inaction creates consumer risk by leaving the market unregulated. He noted that European Food Safety Authority established a safe daily intake level for CBD in 2023, demonstrating that regulatory frameworks are achievable. Aaron Smith, co-founder and chief executive of the National Cannabis Industry Association, stated in July 2026 that intoxicating hemp products represent "a massive regulatory failure" that undermines state marijuana programs and creates public health risks. Smith said that products containing 95% delta-8 THC sold without age verification or testing requirements are "fundamentally incompatible with responsible cannabis policy" and that federal restrictions are necessary to protect consumers and preserve state regulatory authority. He called for comprehensive federal cannabis legalization that would regulate all intoxicating cannabinoids under a unified framework with testing, labeling, and taxation requirements. Dr. Marielle Weintraub, president of the American Academy of Pediatrics' Committee on Substance Use and Prevention, testified before Congress in June 2026 that intoxicating hemp products pose particular risks to adolescents due to developing brain vulnerability to THC exposure. Weintraub cited emergency department data showing a 340% increase in pediatric exposures to delta-8 THC products between 2021 and 2025, with cases involving accidental ingestion of gummies and vape products. She recommended federal regulations including child-resistant packaging, potency limits, and prohibition of products designed to appeal to minors. Professor Robert Mikos of Vanderbilt Law School, an expert on federalism and drug policy, said in an August 2026 law review article that the 2018 Farm Bill's preemption of state restrictions on hemp commerce creates constitutional tensions with state police powers. Mikos argued that while Congress can remove hemp from the Controlled Substances Act, the extent to which federal law prevents states from regulating intoxicating hemp products remains legally uncertain. He noted that courts have not definitively resolved whether the 2018 Farm Bill's commerce clause protections extend to products that are intoxicating despite meeting the 0.3% delta-9 THC definition.

What's Next: Regulatory Timeline and Scenarios

The federal hemp regulatory landscape will likely transform significantly between late 2026 and early 2028 through coordinated agency rulemaking, potential legislation, and ongoing litigation. The USDA and DEA are expected to publish proposed rules on intoxicating hemp cannabinoids by December 2026, according to statements from agency officials in June 2026. The rulemaking process will include a public comment period of 60-90 days, followed by review and potential revision before final rules are published. Based on typical agency timelines, final rules would likely take effect in mid-to-late 2027, though emergency interim final rules could be implemented more quickly if agencies determine that public health requires immediate action. Industry sources anticipate that the rules will prohibit or severely restrict delta-8 THC, delta-10 THC, THC-O acetate, THCP, and HHC by classifying them as controlled substances or establishing that chemical conversion processes render products non-compliant with the 2018 Farm Bill. The most significant uncertainty involves THCA flower: some regulatory scenarios would prohibit high-THCA hemp by measuring total THC after decarboxylation, while others might maintain the current testing standard that measures only delta-9 THC in raw plant material. Congressional action remains possible but uncertain. The Hemp Advancement Act of 2026, introduced in the House in July 2026, would explicitly protect all hemp-derived cannabinoids from DEA scheduling and establish an FDA regulatory pathway for CBD in food. The bill has 47 co-sponsors but has not advanced from committee. Conversely, the Intoxicating Hemp Products Control Act, introduced in the Senate in August 2026, would prohibit products designed to induce intoxication and require FDA pre-market approval for all ingestible hemp products. This bill has 12 co-sponsors and similarly remains in committee. Litigation will likely challenge any new restrictions. Hemp industry groups have indicated they will file suit arguing that the 2018 Farm Bill legalized all derivatives of compliant hemp and that agencies lack authority to prohibit specific cannabinoids through rulemaking. These cases would likely focus on Administrative Procedure Act claims that rules exceed statutory authority or are arbitrary and capricious. Resolution could take 2-4 years as cases proceed through district courts and appeals. State-level developments will continue regardless of federal action. Minnesota implemented a comprehensive intoxicating hemp regulatory framework in July 2023 that serves as a model for other states, including potency limits (5mg THC per serving, 50mg per package for edibles), testing requirements, age restrictions, and retailer registration. North Carolina enacted similar regulations in 2025. Additional states are expected to adopt regulatory frameworks in 2027 legislative sessions, particularly if federal rules are delayed. Market consolidation is likely as regulatory uncertainty and compliance costs favor larger, well-capitalized companies. Small retailers and manufacturers may exit the market or be acquired by MSOs or consumer packaged goods companies with resources to navigate complex regulations. The CBD market may see increased investment if FDA provides regulatory clarity, while the intoxicating hemp segment faces contraction if federal restrictions are implemented.

State-by-State Breakdown of Hemp Regulations

State hemp policies vary dramatically in cultivation requirements, product regulations, and approaches to intoxicating cannabinoids, creating a complex compliance landscape for interstate businesses.

California

California operates a USDA-approved hemp cultivation program administered by the California Department of Food and Agriculture. The state requires registration fees of $900-1,500 annually depending on acreage and mandates testing within 30 days of harvest. For products, Assembly Bill 45 (2023) established comprehensive regulations for hemp-derived cannabinoid products, including age restrictions (21+), a 0.3% total THC limit per serving, testing requirements, and prohibition of synthetic cannabinoids. The law took effect in 2024, requiring retailers to obtain state licenses. California has approved approximately 1,200 hemp cultivation licenses and 3,400 product manufacturer licenses as of 2026.

Colorado

Colorado pioneered hemp cultivation under the 2014 Farm Bill pilot program and operates a USDA-approved plan through the Colorado Department of Agriculture. The state has banned delta-8 THC and other intoxicating hemp cannabinoids, with regulations specifying that only non-intoxicating hemp products are legal. Colorado's Marijuana Enforcement Division treats intoxicating hemp products as marijuana requiring licensed dispensary sales. The state licenses approximately 800 hemp farmers cultivating 18,000 acres, primarily for CBD extraction. Colorado's strict approach reflects its mature marijuana market, where regulators prioritize protecting licensed cannabis businesses from hemp competition.

Florida

Florida operates under a USDA-approved hemp program administered by the Department of Agriculture and Consumer Services. The state has not enacted specific restrictions on intoxicating hemp cannabinoids, creating a largely unregulated market with products available in gas stations and convenience stores statewide. Florida's hemp industry includes approximately 2,100 licensed cultivators and 8,500 registered hemp product manufacturers. The state's large population and lack of adult-use marijuana legalization have made it the largest market for intoxicating hemp products nationally, with estimated 2025 sales of $1.8 billion. Legislative proposals to regulate intoxicating hemp products failed in the 2025 and 2026 sessions due to industry lobbying.

Kentucky

Kentucky has deep agricultural ties to hemp and operates a USDA-approved program through the Department of Agriculture. The state licenses approximately 1,000 hemp farmers cultivating 12,000 acres, making it one of the top five production states. Kentucky has not enacted specific restrictions on intoxicating hemp cannabinoids, though the state requires product registration and testing for contaminants. The Kentucky Hemp Association has advocated for federal regulatory clarity while opposing state-level prohibitions. Hemp has become an important crop for tobacco farmers transitioning to alternative commodities, with the state investing in processing infrastructure and research at the University of Kentucky.

New York

New York operates a USDA-approved hemp cultivation program and has banned delta-8 THC